Detalhe da pesquisa
1.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lancet HIV
; 11(4): e222-e232, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538161
2.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infect Dis
; 8(9): ofab439, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34557563
3.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
PLoS One
; 14(11): e0225199, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725787
4.
Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.
Antimicrob Agents Chemother
; 48(8): 2825-30, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15273087